Insider Trading June 24, 2026 05:51 PM

Arvinas CFO Andrew Saik Sells $46,473 in Company Stock

Automatic execution of restricted stock units covers tax obligations as company navigates mixed Q1 results

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
ARVN

Arvinas Inc. reported that Chief Financial Officer Andrew Saik sold 5,696 shares of the company's common stock on June 24, 2026, in a transaction valued at $46,473. The sale, executed automatically to cover tax withholding obligations, follows the vesting and settlement of 25% of Saik's restricted stock units granted on the same date. This transaction does not represent a discretionary trade by the executive. Arvinas, a biotechnology firm, recently reported its first quarter 2026 earnings, with an EPS of -$0.90 beating analyst expectations of -$0.93, but revenue of $15.6 million falling short of the anticipated $17.16 million. The stock has declined 32% year-to-date, trading at $8.06, though some analysis suggests it may be undervalued.

Arvinas CFO Andrew Saik Sells $46,473 in Company Stock
ARVN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CFO Andrew Saik sold 5,696 shares for $46,473 in an automatic transaction to cover tax obligations related to vested RSUs.
  • Arvinas reported Q1 2026 EPS of -$0.90, beating expectations of -$0.93, but revenue of $15.6 million missed the forecast of $17.16 million.
  • The stock has declined 32% year-to-date, trading at $8.06, though some analysis suggests it may be undervalued relative to its Fair Value.

Andrew Saik, serving as the Chief Financial Officer for ARVINAS, INC. (NASDAQ:ARVN), executed a sale of 5,696 shares of the company's common stock on June 24, 2026. The total value of this transaction was $46,473. Following the completion of this sale, Mr. Saik's direct holdings in ARVINAS, INC. common stock stand at 187,432 shares. The transaction occurred at a price of $8.159 per share, which was slightly above the stock's recent closing price of $8.06. The stock has experienced a significant decline of 32% year-to-date. Analysis from InvestingPro indicates that the stock is currently trading well below its calculated Fair Value, placing it on the platform's list of Most Undervalued stocks.

The company clarified that this sale was automatically executed to cover tax withholding obligations. The sale was directly connected to the vesting and settlement of 25% of Mr. Saik's restricted stock units (RSUs) that were granted on June 24, 2024. The transaction was carried out pursuant to a durable sale instruction, and the company explicitly stated that it does not represent a discretionary trade by Mr. Saik.

In recent financial reporting, Arvinas Inc. disclosed its earnings for the first quarter of 2026. The company posted an earnings per share (EPS) of -$0.90. This result slightly exceeded analyst expectations, which had forecasted an EPS of -$0.93. However, the company's revenue for the quarter was reported at $15.6 million, falling short of the anticipated $17.16 million. Despite the positive EPS surprise, the revenue shortfall has drawn attention from investors. Arvinas' stock initially saw a modest increase in pre-market trading but later experienced a decline. These developments reflect mixed reactions from the investment community. The earnings report highlights the company's ongoing challenges in meeting revenue expectations.

Risks

  • Revenue shortfall in Q1 2026 highlights ongoing challenges in meeting financial expectations, potentially impacting investor confidence.
  • Mixed market reaction to earnings, with initial pre-market gains followed by a decline, indicates uncertainty among investors.
  • The stock's significant year-to-date decline of 32% reflects broader market pressures on the biotechnology sector.

More from Insider Trading

Faeth Therapeutics CFO Brian Stephenson Executes $406K Stock Purchase Amid Analyst Upgrades Jun 24, 2026 Ooma Director Russell Mann Executes $367K Stock Disposal Jun 24, 2026 Faeth Therapeutics CEO Anand Parikh Expands Holdings Through Cash Purchase and Option Exercises Jun 24, 2026 HRT Financial LP Executes Dual Aditxt Transactions Amidst Corporate Restructuring Jun 24, 2026 Asana's Chief Accounting Officer Veronica Sosa Executes Stock Sale to Cover Tax Liabilities Jun 24, 2026